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Abstract
Background: We have previously shown that angiopoietin-like 4 (angptl4) mRNA, a hypoxia-inducible gene, is highly
expressed in clear cell renal-cell carcinoma (ccRCC), the most common subtype of RCC for which no specific marker is
available. We here investigated whether angptl4 mRNA 1) could be a useful diagnostic and/or prognostic marker of ccRCC in
a large and comprehensive retrospective series, 2) induction is dependent on the VHL status of tumors.
Methodology/Principal Findings: Using in situ hybridization, we report that angptl4 mRNA is expressed in 100% of both
sporadic (n=102) and inherited (n=6) primary ccRCCs, without any statistical association with nuclear grade (p=0.39),
tumor size (p=0.09), stage grouping (p=0.17), progression-free survival (p=0.94), and overall survival (p=0.80). Angptl4
mRNA was also expressed in 26 (87%) of 30 secondary ccRCCs but neither in any other secondary RCCs (n=7). In contrast,
angptl4 mRNA was neither expressed in 94% non-ccRCC renal tumors (papillary RCCs (n=46), chromophobe RCCs (n=28),
and oncocytomas (n=9)), nor in non-renal clear cell carcinomas (n=39). Angptl4 expression was also examined in tumors
associated (n=23) or not associated (n=66) with VHL disease. 40 (98%) hemangioblastomas expressed angptl4 whereas all
pheochromocytomas (n=23) and pancreatic tumors (n=25) were angptl4-negative, whatever their VHL status.
Conclusions/Significance: Angptl4 mRNA expression was highly associated with ccRCC (p=1.5 10
249, Chi square test)
allowing to define its expression as a diagnosis marker for primary ccRCC. Moreover, angptl4 mRNA allows to discriminate
the renal origin of metastases of clear-cell carcinomas arising from various organs. Finally, inactivation of VHL gene is neither
necessary nor sufficient for angptl4 mRNA induction.
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Introduction
Renal-cell carcinoma (RCC) represents 2% of all malignant
diseases in adults and is the third most common genitourinary
cancer site, after prostate carcinoma and transitional cell carcinoma
of the urinary bladder [1]. RCC is estimated to account for 2.3% of
all cancer-related deaths; this corresponds to ,26,400 patients in
Europe [2] and ,102,000 in the world [3,4]. The histological
subtypes ofRCCarenumerous, principallyrepresented byclearcell
RCC (ccRCC), papillary RCC (pRCC), chromophobe RCC
(chRCC), and carcinoma of the collecting ducts. Moreover, several
benign renal tumors are also described, including oncocytoma,
papillary adenoma, and angiomyolipoma [5].
Clear cell RCC (ccRCC), the most common subtype of RCC,
represents more than 75% of all cases [5,6]. An early event during
the evolution of ccRCC is loss of function of the von Hippel-
Lindau (VHL) gene, a tumor suppressor gene located on 3p25.3
[6]. The best documented function of the VHL gene product,
pVHL, relates to its role as the substrate recognition module of an
ubiquitin ligase complex that targets the a-subunit of hypoxia-
inducible factor (HIF) for destruction in the proteasome. Through
transcriptional regulation, HIF enhances glucose uptake and
increases expression of angiogenic, growth, and mitogenic factors
including vascular endothelial growth factor (VEGF), platelet
derived growth factor b polypeptide (PDGFb), erythropoietin, and
transforming growth factor a (TGFa) [7,8]. Several HIF-
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Germline mutations of the VHL gene are responsible for the VHL
disease, an autosomal dominant hereditary disorder characterized
by the development of benign and/or malignant tumors in
different organs. VHL-associated tumors include central nervous
system hemangioblastoma, retinal angioma, pheochromocytoma,
pancreatic endocrine and serous tumors, endolymphatic sac
tumor, papillary cystadenoma of epididymis and broad ligament,
and renal cysts and multifocal or bilateral ccRCC; which is the
major cause of death of VHL patients [8].
Most renal tumors can be diagnosed by experienced patholo-
gists on the basis of hematoxylin and eosin (H&E) morphology
alone. Nevertheless, a morphologic overlap exists between the
different histological subtypes of RCC, and sometimes renal
oncocytoma and epithelioid angiomyolipoma enter into the
differential diagnosis. Since RCC subtypes have different malig-
nant potential, prognoses and optimal therapies [10], many
markers have been tested to support an accurate histological
classification, including CD10, RCC marker (RCCma), CK7,
CD117, CA9 and AMACR. Unfortunately, none of these markers
is to date specific for one subtype of renal epithelial tumor
[10,11,12,13]. Different panels of markers for differential diagnosis
of renal epithelial tumors have also been proposed [14,15].
Nevertheless, they are heterogeneous in number and nature of
markers, and so far they have a limited application for daily
practice.
Besides, the improvement of imaging techniques for small
tumors detection and the increasing use of minimally invasive
destructive technology (ie, radiofrequency and cryotherapy)
require imaging-guided renal biopsy to analyse these renal tumors.
The need of sensitive and specific diagnostic markers becomes
even more evident in this context.
Angiopoietin-like 4 (ANGPTL4), initially known as hepatic
fibrinogen/angiopoietin-related protein (HFARP), peroxisome
proliferator-activated receptor-c (PPARc) angiopoietin-related
gene (PGAR), or fasting-induced adipose factor (FIAF), is a
secreted glycoprotein which structurally belongs to the angiopoie-
tin/ANGPTL family [16]. This protein family comprises at least
11 members with a molecular weight of 44 to 58 kDa. Human
ANGPTL4 consists of 406 amino acids protein with a signal
peptide directing secretion, an amino-terminal coiled-coil domain,
a linker, and a carboxy-terminal fibrinogen-like domain [17,18].
The most studied function of ANGPTL4 is its role in the
regulation of lipid metabolism, particularly as inhibitor of
lipoprotein lipase activity [18]. Its role in vascular and tumor
processes is more debated [16,17,19], and suggestive of a context,
tissue specific activity of ANGPTL4.
Our laboratory has previously shown that ANGPTL4 is a
hypoxia-inducible gene. Indeed, angptl4 mRNA is expressed in
ischemic tissues and in the perinecrotic areas of different human
tumors. Interestingly, it is also highly up-regulated in ccRCC [20].
The present study was designed first, to determine whether
angptl4 mRNA expression is a useful marker of ccRCC in a large
and comprehensive retrospective series of primary and metastatic
renal tumors, including the uncommon subtypes; second, to
evaluate whether angptl4 mRNA expression is able to determine
the renal origin of metastatic clear cell carcinomas by analysing
angptl4 mRNA expression in non-renal clear cell carcinomas; third,
to determine whether angptl4 mRNA expression has any
prognostic value in ccRCC; and fourth, to define whether the
induction of angptl4 mRNA expression in human tumors is
dependent of VHL pathway by examining both the VHL status of
a subgroup of angptl4- positive RCC and angptl4 mRNA expression
in the main non-renal VHL disease-related tumors. Our study
demonstrates that angptl4 mRNA expression is a diagnostic marker
of primary and metastatic ccRCC but has no prognosis value.
Moreover, inactivation of VHL gene is neither necessary nor
sufficient for angptl4 mRNA induction.
Methods
Patients and tumor samples
Renal tumors. All formalin-fixed, paraffin-embedded
samples of primary renal tumors obtained from patients who
underwent radical or partial nephrectomy at Ho ˆpital Saint-Louis
(Paris, France) during the 2002–2006 period were gathered for this
study. The inclusion of uncommon subtypes of renal tumors was
extended to the 2000–2008 period. Finally, renal pediatric tumors
and 5 cases of VHL disease-associated ccRCC with a documented
germline mutation were retrieved from the files of the departments
of Pathology of Ho ˆpital Pontchaillou (Rennes, France), and
Ho ˆpital de Bice ˆtre (Kremlin-Bice ˆtre, France), respectively. One
pathologist (JV) reviewed the H&E sections of all primary renal
tumors (n=253) and determined the histopathological diagnosis
according to the current 2004 World Health Organization
classification [5]. These tumors included 108 ccRCCs (42.7%,
sporadic ccRCCs [n=102], ccRCCs associated with VHL disease
[n=5] or tuberous sclerosis complex (TSC) [n=1]), 3 multilocular
cystic RCCs (1.2%), 46 pRCCs (18.2%, type 1 [n=32], type 2
[n=10], and oncocytic variant [n=4]), 3 mucinous tubular and
spindle cell carcinomas (1.2%), 28 chRCCs (11%), 2 hybrid
oncocytic tumors in Birt-Hogg-Dube (BHD) syndrome (0.8%), 2
carcinomas of the collecting ducts (0.8%), 1 medullary carcinoma
(0.4%), 2 Xp11.2 translocation carcinomas (0.8%), 6
nephroblastomas (Wilm’s tumors) (2.4%), 2 clear cell sarcomas
(0.8%), 4 urothelial carcinomas of the renal pelvis (1.6%), 9
oncocytomas (3.5%), 12 angiomyolipomas (4.7%), 11 papillary
adenomas (4.3%), 3 metanephric adenomas (1.2%), 1 cystic
nephroma (0.4%), 4 renomedullary interstitial cell tumors (1.6%)
and 1 mixed epithelial and stromal tumor (0.4%). Five clear cell
papillary RCCs (ccpRCCs; 2%), a new entity recently described
[5], were finally included in the study. The nuclear grade was
determined using the criteria of Fuhrman [21]. Renal cancers
were staged according to the International Union Against Cancer
2002 TNM classification [22]. The clinical data and follow-up of
patients with sporadic ccRCC were collected from the clinical
records of patients.
Thirty-four samples of RCC in metastatic location (28 ccRCCs;
4 pRCCs, type 1 [n=1], type 2 [n=3]; 1 chRCC; 1 medullary)
and 3 local recurrences (ccRCCs [n=2], chRCC [n=1]) were
also gathered for this study. Among them, 20 occurred in patients
whose primary tumor was included in the present study, and 17
came from biopsy or resection of metastatic tumors only. Finally,
the renal parenchyma adjacent to the tumor was used as a source
of normal renal tissue.
Non-renal VHL disease-related tumors. Forty-one
hemangioblastomas and 25 pancreatic tumors (19 endocrine and
6 serous tumors) retrieved from the archives of the Departments of
Pathology of CHU de Nancy (Nancy, France), and Ho ˆpital
Beaujon (Clichy, France) were collected for this study. Among
these tumors, 5 hemangioblastomas, and 13 pancreatic tumors (13
endocrine and 2 serous tumors) were VHL disease-associated
tumors with a documented germline mutation in the VHL gene.
All hemangioblastomas and VHL disease-associated pancreatic
tumors included in this study were previously reported in 2 distinct
studies [23,24].
In addition, 23 apparently sporadic pheochromocytomas,
carrying no evidence of underlying inherited tumor syndromes,
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neurofibromatosis type 1, and the pheochromocytoma–paragan-
glioma syndrome, were provided by the Pathology department of
Ho ˆpital Saint-Louis (Paris, France).
Non-renal clear cell carcinomas. Twelve ovarian clear cell
adenocarcinomas, 20 endrometrial clear cell adenocarcinomas,
and 7 clear cell variants of lung carcinoma (adenocarcinomas
[n=5] and epidermoid carcinomas [n=2]) were obtained from
the Departments of Pathology of Pasteur Cerba (Cergy-Pontoise,
France), and CHU de Nancy (Nancy, France).
The study was approved by the Institutional Review Board
(Ho ˆpital Saint-Louis, Paris, France). Written informed consent was
obtained for the study according to the National Institute of
Cancer professional recommendations and the French Law of
August 2004 (loi 2004-800 du 6 aou ˆt 2004) and according to the
Declaration of Helsinki Principles.
Procedures
In situ hybridization. 5-mm tissue sections were mounted on
superfrost plus slides. The detailed protocol for in situ hybridization
has been previously published [20]. Observation was performed
under a microscope with dark field or bright field illumination.
The angptl4 mRNA expression level was evaluated in a blinded
fashion using sense probe as a negative control. in situ
hybridization allows to determine angptl4 mRNA-positive cell-
types (ie, tumor or stromal cells). The extent and the intensity of
signal were evaluated using a semiquantitative scoring method as:
0=absent; 1=mild and focal; 2=moderate and focal; 3=strong
and focal; and 4=strong and diffuse, in comparison to the same
ccRCC specimen (score 3) which was systematically included in
each hybridization series and was therefore used as a reference in
each hybridization series.
VHL gene status analyses. VHL gene status analyses were
performed without knowledge of any pathological or clinical data
in 2 independent experiments. For each case, ten 7-mm sections of
formalin-fixed paraffin-embedded tissue blocks were obtained
from paired tumor and normal tissue specimens containing .90%
of tumor cells and no tumor cells, respectively. DNA was extracted
using the QIAamp DNA Mini Kit (Qiagen, Courtaboeuf, France)
according to the manufacturer instruction.
For VHL gene mutation analysis, PCR based amplification of
each of the 3 coding exons was performed on a Lightcycler 2.0
System (Roche) using SyberGreen Master Mix (Roche). Two
hundred ng genomic DNA were amplified according to conditions
and using primers listed in Table S1. Amplicons were then purified
and sequenced on both strands using the BigDye Terminator v3.1
kit (Applied Biosystems, conditions: 96uC, 5mn, 1 cycle, 96uC,
10 sec, 60uC 5 sec, 60uC 4mn, 25 cycles) and analysed on a 3130
Genetic Analyser (Applied Biosystems). The resulting sequences
were compared to that of 3 VHL exons using the SeqScape
software (Applied Biosystems). The identified mutations were
compared to mutations described in the VHL database (http://
www.umd.be/VHL/).
For microsatellite analysis, allelotyping of a physical distance of
approximately 6.5 Mb between markers D3S1560 and D3S3611
was performed using 6 polymorphic microsatellite markers
flanking VHL gene and listed in the UCSC database in the order
telomeric to centromeric 3p: D3S1560 (3p26.2), D3S1597
(3p25.3), D3S1317 (3p25.3), D3S1435 (3p25.3), D3S1038
(3p25.3), and D3S3611 (3p25.3). VHL gene is located between
D3S1597 and D3S1317. The primer sequences used for PCR
analyses are listed in Table S2. One primer of each microsatellite
marker was end-labelled with one of the following fluorophores: 6-
FAM, NEDH or HEX (Applied Biosystems). PCR was conducted
as follows: for each microsatellite marker, equal amounts of DNA
(20 ng each of constitutional and tumor-extracted) were subjected
simultaneously in 2 different PCR tubes to one cycle of soaking at
95uC in a GeneAmp PCR System 9700 (Applied Biosystems), then
to 40 cycles of amplification at 95uC for 30 sec and 60uC for
1 min. The amplification was terminated by a final extension step
at 72uC for 10 min. The resulting PCR products were analysed on
an Applied Biosystems 3130xl genetic analyser using the
GeneMapper software. This technique allowed the estimation of
allele size and the quantitative evaluation of allele ratio.
Homozygous markers were quoted ‘‘not informative’’. Informative
cases were scored as LOH when the intensity of the signal for one
allele in tumor tissue specimens was decreased by .50% in
comparison to allelic signal observed in normal tissue specimens.
Allelic imbalance was scored when the signal for one allele was
decreased .20% and ,50%.
Statistical analysis
Analyses were performed using R packages (The R Project for
Statistical Computing, version 2.10.1). The performance of angptl4
mRNA expression for diagnostic of ccRCC was assessed by
considering the number of correctly classified (true positives, TP,
and true negatives, TN) and incorrectly classified (false positives,
FP, and false negatives, FN) cases, and a Chi-square test was
performed. The correlation studies between angptl4 mRNA
expression level and the main histological prognostic factors of
ccRCC (ie, Fuhrman nuclear grade, 2002 AJCC TNM stage
groupings, and tumor size), between angptl4 mRNA expression
level and VHL mutations were statistically analysed using the
Fisher’s exact test for qualitative variables and the Kruskal-Wallis
K test for quantitative variables (R-package ‘‘stats’’). Progression–
free survival (PFS) and overall survival of patients with ccRCC
were estimated by the Kaplan-Meier method (R-package
‘‘survival’’). PFS was defined as the time from start of therapy to
the occurrence of local recurrence or distant metastases. Overall
survival was defined as the time from start of therapy to death due
to any cause. For each test, only p values lower than 0.05 were
considered statistically significant.
Results
Angptl4 mRNA is a diagnostic marker of primary and
secondary ccRCCs
Angiopoietin-like 4 mRNA expression was assessed in 253 primary
renal tumors using in situ hybridization which allowed us to
determine both expression level and the cell types that express it.
Heteregenous expression of angptl4 mRNA was detected in all 108
cases (100%) of ccRCCs, independently of their sporadic or
inherited (VHL or TSC diseases) origin (Figure 1A, B; Table 1).
Expression was systematically detected in tumor cells but not in
stromal cells (ie, endothelial and inflammatory cells, myocytes,
fibroblasts and myofibroblasts). Angptl4 mRNA expression was also
detected in 26 cases (86.7%) of 30 metastases or local recurrence of
ccRCC, as shown in Figure 1C, D. The primary tumor was
available in 14 of these 30 secondary ccRCCs. By comparison to
the primary tumor, the expression level in secondary tumor was
similar in 10 cases (71.4%), weaker in 1 case (7.1%), and absent in
3 cases (21.5%).
In addition to ccRCC, angptl4 mRNA was detected in all other
clear cell renal epithelial tumors (n=8) included in the present
study. Indeed, all 3 cases (100%) of cystic multilocular RCC
(figure 1E, F), and all 5 cases (100%) of ccpRCC (figure 1G, H)
expressed angptl4 mRNA. In addition, 1 nephroblastoma also
expressed angptl4 mRNA in a focal area of small cysts lined by
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was negative.
In contrast, angptl4 mRNA was never expressed in the other
benign (n=41) and malignant (n=95) primary renal tumors,
including pRCCs (figure 1I, J), chRCCs (figure 1K, L), and
oncocytomas. All 7 secondary non-clear cell RCCs (2 chRCCs, 4
pRCCs, 1 medullary carcinoma) were also negative for angptl4
mRNA expression.
Besides, as previously described [20], angptl4 mRNA expression
was detected in the perinecrotic region of several types of primary
renal tumors, represented essentially by pRCCs and ccRCCs, and
in some metastases of RCC. This mRNA expression pattern was
not specific of a subtype of renal tumors but depended on the
existence or not of necrotic areas in tumors. These angptl4-positive
perinecrotic areas were very limited and not considered in the
determination of angptl4-positive or negative tumors.
Finally, normal renal tissue adjacent to the tumor rarely
expressed angptl4 mRNA (7.4% of cases), in some distal and
collector tubules.
In summary, in this large and comprehensive series, angptl4
mRNA expression was expressed in 100% of ccRCCs and in only
6.8% of non-ccRCC renal tumors. Thus, angptl4 mRNA
expression was highly associated with ccRCC (p=1.5 10
249, Chi
square test). The angptl4 mRNA expression was also limited to
ccRCC subtype in local recurrence and metastatic cases of RCC
(ie, 86.7% [26 of 30] positive in secondary ccRCCs, and 0% [0 of
7] positive in non-ccRCC secondary renal tumors).
Since differential diagnosis of metastatic clear cell carcinomas is
oftendifficult,wealsoanalysedangptl4mRNAexpressionin12cases
of ovarian clear cell adenocarcinoma, 20 cases of endometrial clear
cell adenocarcinoma, and 7 cases of clear cell variants of lung
carcinoma.Noneofthesetumorsexpressedangptl4mRNA(Table2).
Angptl4 mRNA has no prognostic value in ccRCCs
In order to determine whether angptl4 mRNA level had a
prognostic value in ccRCC, a correlation study was performed in all
sporadic ccRCC cases (n=102), independently of clinical data and
follow-up of the patients. The levels of angptl4 mRNA expression
were not significantly different between low (G1/G2) vs. high (G3/
G4) Fuhrman nuclear grade (p=0.39, see Table 3). Also, angptl4
mRNA expression level was not statistically associated with tumor
size (p=0.09), and 2002 AJCC TNM stage grouping (p=0.17). The
follow-up of patients with ccRCC ranged from 1 to 99 months after
tumor surgical resection, with a mean (standard deviation) of 36.2
(25.5) months (see Table 3). In this study, the estimate probabilities
of both local recurrence or distant metastases, and death by five
years was 0.35 (95% CI 0.22 to 0.46), and 0.21 (95% CI 0.10 to
0.31), respectively. The outcome of these patients showed no
difference in the occurrence of local recurrence and/or metastases
accordingtoangptl4mRNAexpressionlevel(score1vs.score2–3vs.
score 4; p=0.97). No difference was also observed in PFS (p=0.94),
and overall survival (p=0.80).
Angptl4 mRNA induction is independent of VHL gene
inactivation
The contribution of VHL alterations in angptl4 mRNA
expression was assessed in human tumors by analysis of the VHL
Figure 1. In situ hybridization analysis of angptl4 mRNA expression in renal tumors. H&E (A) and dark-field (B) views of angptl4 mRNA
expression in ccRCC (64). Bright-field (C) and dark-field (D) views of lymph node metastasis of ccRCC (610). Bright-field (E) and dark-field (F) views of
angptl4 mRNA expression in multilocular cystic RCC (610). Bright-field (G) and dark-field (H) views of angptl4 mRNA expression in ccpRCC (610).
Bright-field (I) and dark-field (J) views of angptl4 mRNA expression in type 2 pRCC (610). Bright-field (K) and dark-field (L) views of angptl4 mRNA
expression in chRCC (610). Note: Strong expression of angptl4 mRNA in primary (A, B) and secondary ccRCC (C, D), in multilocular cystic RCC (E, F),
and in ccpRCC (G, H). Absence of angptl4 mRNA expression in type 2 pRCC (I, J), and chRCC (K, L).
doi:10.1371/journal.pone.0010421.g001
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analysis of the 3 coding exons of the VHL gene and a search for an
allelic imbalance or LOH in the VHL gene locus were performed
on paraffin-embedded or frozen tissue specimens. Forty-six cases
(90.2%) were available for sequencing analysis. A VHL gene
intragenic mutation was noted in 21 cases (45.6%), including 1
case with a biallelic mutation (case nu38, Table 4). The majority
(63.6%) of these mutations corresponded to single-nucleotide
substitutions (missense and nonsense mutations).
The result of LOH at the VHL gene locus is shown in Table 5.
Fifty cases were available for LOH analysis. Six cases (12%) were
not informative (cases nu1, 27, 42, 57, 60, and 68, Table 5). Two
cases (nu53 and 99, Table 5), with homozygous markers in normal
tissue specimen, presented one allele with a deletion of some base-
pairs in tumor tissue specimen and were considered as informative
cases with allelic mutation. Thus, 43 (97.7%) of the 44 informative
ccRCCs showed a LOH, an allelic imbalance, or an allelic
mutation at the VHL gene locus. Among them, 19 tumors (44.2%)
presented a VHL mutation detected by sequencing. Moreover, a
VHL gene mutation was noted in 1 of the 6 non informative
ccRCCs (case nu 42, Table 4), and in case nu52, not available for
LOH analysis because of the absence of normal tissue specimen.
Finally, 45 cases (97.8%) out of 46 ccRCCs had a detectable VHL
mutation and/or a LOH at the VHL gene locus. In one case of
informative ccRCC, neither VHL mutation nor LOH at the VHL
gene locus were identified (case nu20, Table 5). This unique case
was also tested for hypermethylation of the promoter region of the
VHL gene and was negative (data not shown). Nevertheless, it
expressed high lvels of angptl4 mRNA (score 3).
Second, the VHL status was also examined in 3 cases of
ccpRCC and in one case of TSC-associated ccRCC since they also
expressed angptl4 mRNA. There was no VHL alteration in
ccpRCC. An allelic imbalance was identified at D3S1317
(3p25.3) and D3S1038 (3p25.3) in TSC-associated ccRCC
whereas the D3S1597 (3p25.3) and D3S1475 (3p25.3) microsat-
ellite markers were not informative. No VHL mutation was
detected in this case.
Third, we analysed angptl4 mRNA expression in the main non-
renal tumors associated with VHL disease (ie, pancreatic
endocrine and serous tumors, pheochromocytoma, and heman-
gioblastoma). No angptl4 mRNA was detected by in situ
hybridization in all pancreatic tumors analysed, independently of
the VHL status of these tumors (Figure 2A, B, Table 2). Also,
angptl4 mRNA was not expressed in the 23 pheochromocytomas of
this study (figure 2C, D). Among them, a missense mutation of the
VHL gene was identified in 3 tumors (13%) which were considered
as pheochromocytomas associated with a type 2c VHL disease
[8,25]. On the other hand, angptl4 mRNA was detected in 40
(97.6%) of 41 cases of hemangioblastoma with a varying signal
intensity. The negative case was associated with VHL disease. The
Table 1. angptl4 mRNA expression in 41 benign and 212 malignant renal tumors.
Renal tumors Number of tumors
angptl4 mRNA-positive
tumors
angptl4 mRNA-negative
tumors
Malignant tumors (n=212)
Clear cell Renal Cell Carcinoma (ccRCC) 108 108 (100%) 0
Sporadic ccRCC 102 102 (100%) 0
VHL-associated ccRCC 5 5 (100%) 0
Tuberous sclerosis complex-associated ccRCC 1 1 (100%) 0
Multilocular cystic RCC 3 3 (100%) 0
Clear cell papillary RCC 5 5 (100%) 0
Papillary RCC 46 0 46 (100%)
Mucinous tubular and spindle cell carcinoma 3 0 3 (100%)
Chromophobe RCC 28 0 28 (100%)
Hybrid oncocytic tumor (BHD) 2 0 2 (100%)
Collecting duct carcinoma 2 0 2 (100%)
Medullary carcinoma 1 0 1 (100%)
Xp11?2 translocation carcinoma 2 0 2 (100%)
Nephroblastoma (Wilm’s tumor) 6 1 (17%)* 5 (83%)
Clear cell sarcoma 2 0 2 (100%)
Urothelial carcinoma of renal pelvis 4 0 4 (100%)
Benign tumors (n=41)
Oncocytoma 9 0 9 (100%)
Angiomyolipoma 12 0 12 (100%)
Papillary adenoma 11 0 11 (100%)
Metanephric adenoma 3 0 3 (100%)
Cystic nephroma 1 0 1 (100%)
Renomedullary interstitial cell tumor 4 0 4 (100%)
Mixed epithelial and stromal tumor 1 0 1 (100%)
*angptl4 mRNA expression is limited to a small and cystic area lined by clear cells.
doi:10.1371/journal.pone.0010421.t001
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expressed angptl4 mRNA moderately in 3 cases and weakly in 1
case. angptl4 mRNA was expressed in stromal cells, which are the
tumor cells in this tumor type, but not in endothelial cells
(figure 1E–F). Normal pancreatic, adrenal, and cerebral tissues
adjacent to tumors did not express angptl4 mRNA. We also studied
vegf mRNA expression in a subgroup of these non-renal VHL
disease-associated tumors in order to confirm that tissue mRNA
Table 2. angptl4 mRNA expression in 89 VHL disease-associated tumors and 39 non-renal clear cell carcinomas.
Tumor types Number of tumors
angptl4 mRNA-positive
tumors
angptl4 mRNA-negative
tumors
VHL disease-associated tumor (n=89)
Hemangioblastoma (n=41)
Sporadic hemangioblastoma 36 36 (100%) 0
VHL disease-associated hemangioblastoma 5 4 (80%) 1 (20%)
Pancreatic tumor
Endocrine tumor (ET) (n=19)
Non VHL disease-associated ET 6 0 6 (100%)
VHL disease-associated ET 13 0 13 (100%)
Serous tumor (ST) (n=6)
Non VHL disease-associated ST 4 0 4 (100%)
VHL disease-associated ST 2 0 2 (100%)
Pheochromocytoma (PCC) (n=23)
Non VHL disease-associated PCC 20 0 20 (100%)
VHL disease-associated PCC 3 0 3 (100%)
Non-renal clear cell carcinoma (n=39)
Ovarian clear cell adenocarcinoma 12 0 12 (100%)
Endometrial clear cell adenocarcinoma 20 0 20 (100%)
Clear cell adenocarcinoma of lung 5 0 5 (100%)
Clear cell epidermoid carcinoma of lung 2 0 2 (100%)
doi:10.1371/journal.pone.0010421.t002
Table 3. Correlation study between angptl4 mRNA expression and prognostic factors and VHL status in sporadic ccRCC patients.
Intensity of angptl4 mRNA expression
Score 1 Score 2–3 Score 4
(n=11) (n=75) (n=16) p-Value
{
Nuclear grade 0.39
G1–G2 3 (7%) 34 (81%) 5 (12%)
G3–G4 8 (14%) 41 (68%) 11 (18%)
TNM Stage grouping 0.17
I–II 4 (6%) 49 (79%) 9 (15%)
III–IV 7 (17%) 26 (65%) 7 (18%)
Tumor size (cm) M (SD)* 4.7 (2.3) 5.9 (3.6) 7.1 (3.4) 0.09
"
Follow-up M (SD)* 22 (17.5) 37.1 (27) 39.9 (22) 0.18
"
Metastasis and/or local recurrence 0.97
No 8 (11%) 53 (73%) 12 (16%)
Yes 3 (10%) 22 (76%) 4 (14%)
VHL gene status 0.01
Mutation 0 12 (57%) 9 (43%)
Wild type 7 (28%) 14 (56%) 4 (16%)
*M (SD): mean (standard deviation).
{Fisher exact Test.
"Kruskall-Wallis Test.
doi:10.1371/journal.pone.0010421.t003
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in all cases (data not shown).
Fourth, we sought to establish a correlation between VHL
mutations and angptl4 mRNA expression level in ccRCC. ccRCCs
with VHL mutation expressed more strongly angptl4 that ccRCCs
without VHL mutation (p=0.01, Table 3). This correlation was
stronger when VHL disease-associated ccRCCs were included in
this correlation study (p=0.004).
Discussion
The present study shows that angptl4 mRNA is a powerful
diagnostic marker of ccRCCs. Indeed, 100% of primary ccRCCs
were angptl4-positive whereas 93.8% of primary non-ccRCC renal
tumors were angptl4-negative (p=1.5 10
249, Chi-square test). By
comparison, the expression of CD10 for primary ccRCC is
reported between 75% to 82%, and is also detected in other
subtypes of RCC [11,13]. Similarly, CA9, a hypoxia-inducible
protein, and Pax-2, a homeogene strongly expressed during kidney
development, are expressed in a high proportion of ccRCCs but
their expression is not limited to ccRCC [10,12]. Finally, although
RCCma is the most widely used marker of RCC, it does not allow
differentiation of the different histological subtypes of renal
epithelial tumors [26]. Angptl4 mRNA expression was also detected
in metastases or local recurrence of ccRCC (86.7% positive in
secondary ccRCCs, and 0% positive in non-ccRCC secondary
RCCs). By comparison, RCCma and Pax-2 were expressed in
70% and 85% of secondary ccRCCs, respectively [26]. Further
prospective studies are now needed to determine angptl4 mRNA
sensitivity, specificity and predictive values in clinical practice.
In addition to ccRCC, angptl4 mRNA is expressed in
multilocular cystic RCC (100% of cases), a putative histological
variant of ccRCC [5], and in ccpRCC (100% of cases). One case
(17%) of nephroblastoma also expressed angptl4 mRNA in a focal
and microcystic area formed of clear cells. Thus, angptl4 mRNA
expression seems to be characteristically associated to clear cell
type of renal epithelial tumors.
Based on this observation, we further collected 39 non-renal
clear cell carcinomas. Indeed, many carcinomas might present a
clear cell variant and to date, there is no specific marker to
differentiate metastatic clear cell carcinoma of one site from
another. The specific diagnosis of origin remains a diagnosis of
exclusion based on morphology and clinical/radiographic find-
ings. We thus analysed angptl4 mRNA level in 12 ovarian clear cell
carcinomas, 20 endometrial clear cell carcinomas, and in 7 clear
cell variants of both epidermoid carcinomas and adenocarcinomas
of lung. No expression of angptl4 mRNA was detected in these
tumors. A recent study showed that Pax-2 more than RCCma,
was an useful marker of metastatic ccRCC in a large series of
tumors with clear cytoplasm [26]. Nevertheless, Pax-2 expression
was noted in 42.9% of clear cell ovarian carcinomas, and no
endometrial clear cell carcinoma was included in this study [26].
Therefore, our results underline the relevance of angptl4 mRNA
expression in the determination of renal origin of metastatic clear
cell carcinomas.
Our laboratory has previously shown that ANGPTL4 prevents
metastases by inhibiting vascular permeability as well as tumor cell
motility and invasiveness in a model of xenografted melanoma
B16F0 cells [16]. More recently, Padua and colleagues reported
Table 4. Somatic mutations of the VHL gene in a subgroup of ccRCCs (n=46).
Tumor
number Type of mutation Exon Coding DNA sequence change Protein change (deduced)
Previously
reported
12 Missense 1 c.233A.T p.Asn78IIe Yes
18 Missense 1 c.257C.T p.Pro86Leu Yes
21 Missense 1 c.234T.G p.Asn78Lys Yes
25 Missense 3 c.473T.G p.Leu158Arg No
26 Frameshift 1 c.192delC p.Ser65ArgfsX2 Yes
32 Frameshift 2 c.345delC p.Leu116PhefsX43 Yes
33 Large rearrangement 22 2 2
38 Missense and nonsense 1 c.[262T.G + 263 G.A] p.[Trp88Glu + Trp88X] Yes
40 Missense 2 c.397C.G p.Thr133Ser Yes
42 Frameshift 2 c.388delGTT p.Val130del Yes
45 Nonsense 1 c.203 C.A p.Ser68X Yes
52 Missense 1 c.241C.T p.Pro81Ser Yes
53 Missense 2 c.367G.T p.Thr123Leu No
62 Frameshift 1 c.322–324delCGC p.Arg107del No
63 Missense 3 c.617T.C p.Ile206Thr No
64 Missense 2 c.446C.A p.Ala149Asp No
67 Missense 1 c.206G.A p.Arg69His No
73 Nonsense 3 c.478G.T p.Glu160X Yes
75 Frameshift 3 c.477delA p.Glu160SerfsX10 Yes
77 Frameshift 1 c.338–349del p.Arg113del+Splice defect No
99 Frameshift 1 c.256delC p.Pro86ProfsX Yes
Mutations are described using ‘p.’ when referring to the VHL protein sequence, and ‘c.’ for the VHL cDNA sequence. Mutations are reported in accordance with the
nomenclature for the description of sequence variations as proposed by the Human Genome Variation Society (www.hgvs.org/mutnomen/).
doi:10.1371/journal.pone.0010421.t004
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in a transforming growth factor-b-dependent manner by altering
endothelial integrity [19]. A hypoxic profile that included 13 genes
such as VEGF and ANGPTL4, has been associated with distant
metastases and might represent an independent predictor of
outcomes in primary breast cancers [27]. Therefore, we have
compared angptl4 mRNA expression in regional or distant
metastasis versus primary tumor of ccRCCs. The angptl4 mRNA
expression level was comparable or sometimes lower than the one
observed in the primary tumor. No difference in angptl4 mRNA
expression was also noted between renal vein tumor thrombus and
the adjacent primary tumor in ccRCC with renal vein extension
(n=20). Moreover angptl4 mRNA expression level was not
statistically associated with the Fuhrman nuclear grade, the tumor
size, or the 2002 AJCC TNM stage groupings (p=0.39, p=0.09,
and p=0.17, respectively). Finally, the follow-up of our patients
shows no difference in the occurrence of local recurrence and/or
metastases (p=0.97), in PFS (p=0.94), and in overall survival
(p=0.80) according to angptl4 mRNA expression level. Therefore,
in this study, angptl4 mRNA level has no significant prognostic
value. This result is in agreement with previous expression profile
studies that did not report differential expression of angptl4 mRNA
between aggressive vs. indolent ccRCCs [28,29,30] and ccRCCs
with early vs. late pulmonary metastases [31]. Nevertheless, further
studies are needed to confirm this point.
As ANGPTL4 is a hypoxia-inducible gene [20], we also
investigated whether angptl4 mRNA expression in human tumors
was dependent on the VHL pathway. 45 (97.8%) out of 46
sporadic ccRCCs presented a VHL mutation and/or a LOH at the
VHL gene locus. These results are in agreement with previous
studies which reported a VHL mutation in 34 to 82.4% and a
LOH at VHL locus in up to 98% of sporadic ccRCCs [6,32,33].
One informative ccRCC case (case nu20, Table 5) showed no VHL
alterations, whereas angptl4 mRNA was highly expressed (score 3).
No VHL alteration was identified in 3 ccpRCCs studied, as
previously described [5]. An allelic imbalance was identified in 2
microsatellite markers (D3S1317 and D3S1038) located on 3p25.3
in the case of TSC-associated ccRCC.
Second, the analysis of angptl4 mRNA expression in the main
types of VHL disease-associated tumors (ie, ccRCC, pancreatic
endocrine and serous tumors, pheochromocytoma, and heman-
gioblastoma) revealed that angptl4 mRNA expression is restricted
to ccRCCs (100% of cases) and hemangioblastomas (97.6% of
cases), independently of the VHL status of these tumors. Our
results therefore show that VHL gene alterations are neither
necessary nor sufficient for angptl4 mRNA expression in human
tumors. Nevertheless, VHL mutations influence angptl4 mRNA
expression level which was higher in VHL-mutated ccRCCs vs.
ccRCCs without VHL mutation (p=0.01).
The present retrospective study might include some potential
bias. Our cohort was intentionally chosen to increase the
frequency of uncommon subtypes of renal tumors in order to
constitute a comprehensive study. Thus, ccRCC represented only
54% of all cases of RCCs examined, whereas the incidence of
ccRCC in daily practice is close to 75% [5,6]. Second, as the
analysis of angptl4 mRNA expression was performed by a single
centre, further multicentre validation study is needed. Third, the
development of anti-ANGPTL4 antibodies for immunohistochem-
Table 5. Results of LOH analysis at the VHL gene locus in a subgroup of sporadic ccRCCs (n=50).
Tumor number
1 9 10 12 13 15 16 18 19 20 21 23 25 26 27 28 29 30 31 32 33 34 37 38 40
Markers
D3S1560 (3p26.2) &%&% 222%%&2 %% 2 &&&222& 2
D3S1597 (3p25.3) 2 & 2 && 2 &%22&&2 &&&&&22&&&
VHL gene
D3S1317 (3p25.3) 2 &&& 2 % 2 &&&2 & & 22 2 %&&
D3S1435 (3p25.3) %&&2 & 222&%2 %&222 && 2 &&&2
D3S1038 (3p25.3) 2 & 2 & 2 & 2 && &&&2 &&&&% &%&&
D3S3611 (3p25.3) & 22&& & %&&&2 2 & 2 &&2 % 2 &
VHL mutation NNNYN2 NYNNYNYY2 NNNNYYNNYY
Tumor number
42 43 45 46 47 53 57 60 62 63 64 65 66 67 68 69 70 71 73 75 76 77 80 82 99
Markers
D3S1560 (3p26.2) 2 && 22 & 22 2 % &&2 & 2 & 2 %*
D3S1597 (3p25.3) 22& & 2* % 22& & 2 && & 22&&&2
VHL gene
D3S1317 (3p25.3) 2 && &%2 % 2 & 2 & 22 & & 2 & 2*
D3S1435 (3p25.3) & 2 &&2 & 2 & 2 & &&% &%&%22 % 2*
D3S1038 (3p25.3) % 2 & & 2 & &&&&%&& & 2 2* *
D3S3611 (3p25.3) &&2 2 2 &&2 &% % 2 & 2 &%
VHL mutation YNYN2 Y 2 NYYYNNYNNNNYYNYN2 Y
&=loss of heterozygosity (LOH). =allelic imbalance. %=conservation of heterozygosity; 2=not informative; *=allele mutated. The presence of VHL gene mutation
(Y=yes or N=no) is also reported.
doi:10.1371/journal.pone.0010421.t005
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chemical markers used in differential diagnosis of primary and
metastatic renal tumors is required before the use of this marker in
current practice in pathology laboratories. Several commercial
anti-ANGPTL4 antibodies were studied by immunohistochemis-
try, but none of them allowed to obtain a specific staining that
correlated with angptl4 mRNA expression.
In summary, this study shows that angptl4 is an accurate marker
for primary ccRCC diagnosis but has no prognosis value for this
RCC subtype. Moreover, angptl4 mRNA expression allows to
discriminate the renal origin of metastases from clear-cell
carcinomas arising from various organs.
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